Author:
Devriese Lot A.,Koch Kevin M.,Mergui-Roelvink Marja,Matthys Gemma M.,Ma Wen Wee,Robidoux Andre,Stephenson Joe J.,Chu Quincy S. C.,Orford Keith W.,Cartee Leanne,Botbyl Jeff,Arya Nikita,Schellens Jan H. M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference30 articles.
1. International Agency on Cancer World Health Organization. Breast Cancer Incidence, Mortality and Prevalence Worldwide in 2008 Summary. 2008. http://globocan.iarc.fr/factsheet.asp . Accessed September 2012.
2. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
3. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057–4065
4. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630–1639
5. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255–6263
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献